ACTIFOLATE™

Actifolate™  is our manufactured calcium salt of L-5-methyltetrahydrofolic or L-methylfolate. As an alternative to folic acid, it offers good stability, solubility and bioavailability.Actifolate™  is also known as L-methylfolate; L-5-MTHF-Ca; L-methylfolate calcium; L-5-Methyltetrahydrofolic acid, calcium salt; [6S]-5-Methyltetrahydrofolic acid, 

calcium salt.   

CAS# : 

151533-22-1 

Formula: 

C20H25N7O6 

Molecular Weight: 

459.463 g/mol

Safer 
Suitable for all kinds of people including MTHFR gene mutation. 
Higher bioavailability 
No need metabolism, can be absorbed directly  

More stable 

Safer 

More suitable solubility

L-5-MTHF-Ca is obtained by the reduction of synthetic folic acid with sodium borohydride, condensation of the resulting tetrahydrofolic acid with formaldehyde, further reduction of the 5,10- MTHF with NaBH4 to L-5-MTHF, and finally crystallization as the calcium salt. 

Calcium L-methylfolate (L-5-MTHF-Ca; CAS Number 151533-22-1) is a source of folate and an alternative to folic acid for use in human food and food supplements. The safety of L-5-MTHF-Ca was evaluated by testing for genotoxicity, subchronic and prenatal developmental toxicity. In in vitro assays L-5-MTHF-Ca was not mutagenic and did not induce other chromosomal events. Additionally, L-5-MTHF-Ca was not genotoxic in the in vivo micronucleus test nor did it induce DNA damage in rat liver cells. In a subchronic toxicity study, rats administered up to 400 mg/kg bw/day of L-5-MTHF-Ca via oral gavage for 13 weeks had no treatment-related mortalities, and no treatment-related effects were identified on behaviour, body weight, food consumption, ophthalmology, haematology, or organ weights. No treatment-related macroscopic or histopathological findings were observed. Calcium and sodium levels increased with increasing dosage, however the slight increases were within historical control ranges and reversible after the recovery period. L-5-MTHF-Ca is neither teratogenic nor embryotoxic. Based on the results of the in vitro and in vivo studies, the safe use of L-5-MTHF-Ca as an ingredient in foods is supported. The no observed adverse effect level was the highest dose in the subchronic toxicity study, i.e. 400 mg/kg bw/day for male and female rats. 

1. Bailey L.B., Gregory J.F. Folate metabolism and requirements. J. Nutr. 1999;129:779–782. [PubMed] [Google Scholar]

2. Shrubsole M.J., Jin F., Dai Q., Shu X.O., Potter J.D., Hebert J.R., Gao Y.T., Zheng W. Dietary folate intake and breast cancer risk: results from the Shanghai Breast Cancer Study. Cancer Res. 2001;61:7136–7141. [PubMed] [Google Scholar]

3. Robinson K., Arheart K., Refsum H., Brattström L., Boers G., Ueland P., Rubba P., Palma-Reis R., Meleady R., Daly L., Witteman J., Graham I. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation. 1998;97:437–443. [PubMed] [Google Scholar]

4. Laurence K.M., James N., Miller M.H., Tennant G.B., Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. Br. Med. J. (Clin. Res. Ed.) 1981;282:1509–1511. [PMC free article] [PubMed] [Google Scholar]

5. Witthöft C.M., Forssén K., Johannesson L., Jägerstad M. Folates - food sources, analyses, retention and bioavailability. Näringsforskning. 1999;43:138–146. [Google Scholar]

6. Scott J. Methyltetrahydrofolate: the superior alternative to folic acid. In: Krämer K., Hoppe P.-P., Packer L., editors. Nutraceuticals in Health and Disease Prevention. Dekker; New York: 2001. pp. 75–90. [Google Scholar]

7. Page R., Robichaud A., Arbuckle T.E., Fraser W.D., MacFarlane A.J. Total folate and unmetabolized folic acid in the breast milk of a cross-section of Canadian women. Am. J. Clin. Nutr. 2017;105:1101–1109. [PubMed] [Google Scholar]

8. Büttner B.E., Witthöft C.M., Domellöf M., Hernell O., Öhlund I. Effect of type of heat treatment of breastmilk on folate content and pattern. Breastfeed. Med. 2014;9:86–91. [PubMed] [Google Scholar]

9. Sherwood K.L., Houghton L.A., Tarasuk V., O’Connor D.L. One-third of pregnant and lactating women may not be meeting their folate requirements from diet alone based on mandated levels of folic acid fortification. J. Nutr. 2006;136:2820–2826. [PubMed] [Google Scholar]

10. Lewis C.J., Crane N.T., Wilson D.B., Yetley E.A. Estimated folate intakes: data updated to reflect food fortification, increased bioavailability, and dietary supplement use. Am. J. Clin. Nutr. 1999;70:198–207. [PubMed] [Google Scholar]